Cambridge-based techbio company Closed Loop Medicine, which develops combination prescription drug and software therapy products that enable personalised dose optimisation, has appointed Kate Woolland as chief operating officer, tasked with guiding organisational and operational delivery of the company’s lead programmes, products and commercial partnerships.

She will lead collaboration across the multidisciplinary team while working with current and future commercial partners to drive delivery of Closed Loop Medicine’s products to market.

Woolland has strategic business experience, including more than 13 years in healthcare. She was previously chief delivery officer at ieso Digital Health, where she led product, design, clinical trial operations, commercial, regulatory and programme management functions. Before that, Woolland was a partner for PA Consulting.

Woolland said: “Leveraging the capabilities of [Closed Loop Medicine’s] incredible technologies to revolutionise the dosing of medicines has the potential to help patients and healthcare professionals better manage health conditions, improve quality of life and health outcomes for millions of people. I am delighted to have the opportunity to play a part in such ground-breaking work.”  

Dr Hakim Yadi, co-founder and chief executive of Closed Loop Medicine, commented: “As chief operating officer, Kate brings a wealth of experience in optimising and improving health systems and helping scale next generation digitally delivered health services from her time at ieso. We are on a mission to provide the right dose of medicine to patients and are excited to have Kate join us on this journey, helping build and develop our team dedicated to dose optimisation and combination products.”